Blood Plasma Fractionation Technology Market Overview
The Blood Plasma Fractionation Technology Market is expanding as demand for plasma-derived therapies, including immunoglobulins, albumin, and coagulation factor concentrates, increases. Rising prevalence of blood disorders, growing awareness of plasma therapies, advancements in fractionation technologies, and expanding healthcare infrastructure are supporting market growth.
According to the WiseGuyReports market report published in April 2026, the global Blood Plasma Fractionation Technology Market was valued at USD 26.5 Billion in 2024 and USD 27.5 Billion in 2025 and is projected to reach USD 40 Billion by 2035, registering a CAGR of 3.8% during 2026–2035. North America held the largest regional position, valued at USD 11 Billion in 2024 and projected to reach USD 15 Billion by 2035. Filtration was valued at USD 10 Billion in 2024 and is projected to reach USD 15 Billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=643842
Key players driving innovation and competitiveness in the Blood Plasma Fractionation Technology Market include:
Kedrion Biopharma
LFB Group
Takeda Pharmaceutical
Catalent
Kamada
Fresenius Kabi
CSL Behring
Sangamo Therapeutics
Emergent BioSolutions
Grifols
Shire
Biomarin Pharmaceutical
Mediware Information Systems
Biotest
Octapharma
The market is being shaped by increasing demand for plasma-derived therapies used in the management of immune deficiencies, bleeding disorders, and other chronic conditions. Technological advancements in fractionation are improving process efficiency, product yield, and quality. Automation, advanced filtration, and purification technologies are also creating opportunities to improve manufacturing capabilities and reduce operational waste.
The Blood Plasma Fractionation Technology Market can be segmented by Technology into Cryoprecipitation, Centrifugation, Filtration, and Ultrafiltration. By Product Type, it includes Immunoglobulin, Albumin, Coagulation Factor Concentrates, and Other Plasma Derivatives. By Application, it covers Therapeutic, Diagnostic, and Research. By End Use, it includes Hospitals, Clinics, Pharmaceutical Companies, and Research Institutions. Regionally, the market covers North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
The growing need for plasma-derived products is creating opportunities for plasma fractionation companies, pharmaceutical manufacturers, biotechnology firms, healthcare providers, and research institutions. Advanced fractionation technologies, AI-enabled process optimization, sustainable manufacturing, expanded plasma collection infrastructure, and collaborations between industry participants can support market differentiation and future growth.
Recent Developments and Market Trends:
Increasing demand for immunoglobulins and coagulation factors is supporting investments in plasma fractionation capacity and technology.
Technological advancements in automated fractionation processes are helping improve yield, efficiency, and consistency while reducing waste.
Filtration is an important technology segment, with its market value projected to increase from USD 10 Billion in 2024 to USD 15 Billion by 2035.
Immunoglobulin demand is increasing because of its applications in immune deficiencies and autoimmune diseases.
North America continues to hold a major market position due to established healthcare infrastructure, research capabilities, and demand for plasma-derived therapies.
Asia Pacific is creating additional opportunities as healthcare investment, awareness of plasma therapies, and access to advanced healthcare technologies increase.
Recent developments highlighted by WiseGuyReports include Grifols’ February 2025 strategic partnership with LFB Group to co-develop and commercialize plasma-derived immunoglobulins in Europe, Kedrion Biopharma’s April 2025 acquisition of a European plasma fractionation facility, and Catalent’s January 2025 contract to manufacture plasma-derived products for a leading biopharmaceutical company.
Reasons to Buy the Report:
Provides comprehensive insights into the Blood Plasma Fractionation Technology Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across cryoprecipitation, centrifugation, filtration, and ultrafiltration technologies.
Offers detailed segmentation analysis across technology, product type, application, end use, and geographic markets.
Includes competitive intelligence covering leading plasma fractionation, pharmaceutical, biotechnology, and healthcare companies.
Supports informed decisions using market forecasts, plasma-derived therapy demand, blood disorder trends, technology advancements, healthcare investment, and regional opportunities.
Future Outlook:
The future of the Blood Plasma Fractionation Technology Market will be shaped by rising demand for immunoglobulins and coagulation factors, increasing prevalence of blood disorders, technological advancements, growing awareness of plasma-derived therapies, and expanding healthcare infrastructure. Filtration is projected to remain an important technology segment, increasing from USD 10 Billion in 2024 to USD 15 Billion by 2035. North America is expected to maintain its leading position, while Asia Pacific is positioned for significant growth as healthcare expenditure and access to plasma-derived therapies increase. The global Blood Plasma Fractionation Technology Market is projected to reach USD 40 Billion by 2035 at a CAGR of 3.8%.
➤➤Explore Our Latest Related Reports:
